Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans - Takeaways - MDSpire

Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans

  • By

  • David E. Mery

  • Guido Tricot

  • Samer Al Hadidi

  • Yihao Zhan

  • Cody Ashby

  • Clyde Bailey

  • Eric R. Siegel

  • Daisy V. Alapat

  • Hongwei Xu

  • Sandra Mattox

  • Caroline Schinke

  • Maurizio Zangari

  • Sharmilan Thanendrarajan

  • Qing Yi

  • Robert Z. Orlowski

  • Frits van Rhee

  • John D. Shaughnessy

  • Fenghuang Zhan

  • October 16, 2025

  • 0 min

Share

  • 1

    Black Americans with multiple myeloma have higher incidence and mortality rates compared to White Americans, highlighting significant racial disparities.

  • 2

    Rigorous matching of Black and White patients on critical prognostic factors allowed for a more accurate evaluation of racial outcomes in multiple myeloma.

  • 3

    After matching, Black Americans and White Americans showed comparable distributions in molecular risk and extent of disease, reducing bias in survival analysis.

  • 4

    Despite matching, Black Americans had lower hemoglobin levels and higher obesity rates compared to White Americans, indicating physiological and demographic differences.

  • 5

    Survival outcomes for Black Americans matched to White Americans were equal, suggesting that treatment equity can mitigate racial disparities in multiple myeloma.

Original Source(s)

Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans

  • by David E. Mery, Guido Tricot, Samer Al Hadidi, Yihao Zhan, Cody Ashby, Clyde Bailey, Eric R. Siegel, Daisy V. Alapat, Hongwei Xu, Sandra Mattox, Caroline Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Qing Yi, Robert Z. Orlowski, Frits van Rhee, John D. Shaughnessy, Fenghuang Zhan

  • October 16, 2025

Related Content

Exploring the Therapeutic Promise of γδ T Cells in Blood Disorders: Bridging Immunobiology and Clinical Innovation

Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min